Avantor Inc Surpasses Analyst Target Price
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: NASDAQ.COM
Avantor Inc's shares recently traded at $9.69, reaching a 20-day high despite the Nasdaq-100 being down 1.30% and the S&P 500 down 0.34%.
The stock's performance is attributed to surpassing the average analyst 12-month target price of $9.67, indicating increased market confidence that may attract more investor interest. Analysts may reassess their targets to reflect improvements in the company's fundamentals, as the target price distribution among 15 analysts ranges from $7.00 to $19.00, suggesting varying market perspectives on Avantor's future performance.
Investors now face a decision: to hold for potentially higher targets or take profits to avoid risks of overvaluation, which will influence future market dynamics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 9.460
Low
8.00
Averages
11.67
High
16.00
Current: 9.460
Low
8.00
Averages
11.67
High
16.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avantor Inc Stock Surpasses Analyst Target Price
- Stock Performance: Avantor Inc's shares recently traded at $9.69, surpassing the average analyst 12-month target price of $9.67, indicating increased market confidence that may attract more investor interest.
- Analyst Reaction: When a stock reaches its target price, analysts typically either downgrade their valuation or raise their target price; the current market response to Avantor may prompt analysts to reassess their targets to reflect improvements in the company's fundamentals.
- Target Price Distribution: Among the 15 analysts covered by Zacks, target prices range from $7.00 to $19.00, with a standard deviation of $3.154, highlighting varying market perspectives on Avantor's future performance, necessitating cautious evaluation by investors.
- Investor Decision-Making: As the stock price exceeds the target price, investors face a choice: to hold on for potentially higher targets or consider taking profits to avoid risks of overvaluation, which will influence future market dynamics.
See More
Avantor Appoints New Executive VP of Quality and Regulatory
- Executive Appointment: Avantor announced the appointment of Gerard Porreca as Executive Vice President of Quality and Regulatory, responsible for global quality assurance, quality systems, and regulatory affairs, aimed at enhancing the company's competitiveness in life sciences and advanced technology sectors.
- Extensive Experience: Porreca brings deep quality and regulatory experience from the life sciences, medical technology, and healthcare industries, having led global product approvals and complex regulatory engagements at Getinge, ensuring compliance in international markets.
- Strategic Importance: Avantor's CEO Emmanuel Ligner emphasized that Porreca's expertise will be crucial for enhancing operational capabilities and delivering mission-critical solutions, further solidifying Avantor's position as a trusted partner in the scientific journey.
- Customer Value Proposition: Porreca stated that quality and regulatory excellence are not just requirements but key value propositions for customers, and he aims to strengthen quality systems through data-driven insights to help clients accelerate the delivery of life-changing breakthroughs.
See More
Avantor Appoints New Executive VP of Quality and Regulatory
- Executive Appointment: Avantor has announced the appointment of Gerard Porreca as Executive Vice President of Quality and Regulatory, responsible for global quality assurance, quality systems, and regulatory affairs, aiming to enhance operational efficiency in the life sciences and advanced technology sectors.
- Extensive Experience: Porreca brings deep expertise in quality and compliance from his previous role at Getinge, where he led global product approvals and complex regulatory engagements, ensuring the company's compliance and competitiveness in international markets.
- Strategic Importance: CEO Emmanuel Ligner emphasized that Porreca's expertise will be vital for enhancing quality systems and delivering mission-critical solutions globally, thereby increasing customer trust and market position.
- Customer Value Proposition: Porreca stated that excellence in quality and regulatory affairs is not just a requirement but a key value proposition for customers, and he aims to leverage data-driven insights to strengthen quality systems and accelerate the delivery of life-changing breakthroughs.
See More
Avantor Q1 2026 Earnings Call Insights
- Financial Performance Exceeds Expectations: Avantor reported $1.581 billion in revenue for Q1 2026, down 4% year-over-year, yet improved execution in Bioscience and Medtech segments led to results surpassing expectations, with management reaffirming full-year guidance, indicating confidence in future growth.
- VWR Business Challenges: VWR Distribution and Services generated $1.15 billion in revenue for Q1, a 5% decline from the previous year; despite improvements in e-commerce traffic and conversion rates, the segment faces market pressures, with gradual growth expected in the second half of 2026.
- BMP Segment Performance: BMP revenue reached $431 million in Q1, down 2% year-over-year, but a book-to-bill ratio exceeding 1.1 indicates future growth potential; management anticipates Q2 will mark the low point for BMP growth amid increased competitive pressures.
- Leadership Changes and Strategic Adjustments: The company is refreshing its leadership team, with approximately 25% of management updated, the CFO set to depart next month, and the addition of a new Chief Digital Officer and Chief Transformation Officer aimed at accelerating the revival plan and enhancing operational efficiency.
See More
AVANTOR STOCK RISES 3.7% FOLLOWING STRONG Q1 EARNINGS REPORT
- Stock Performance: Avantor's shares increased by 3.7% following the announcement of their Q1 earnings report.
- Earnings Report: The rise in stock price was attributed to the company beating earnings expectations for the first quarter.
See More
Avantor Reports Strong Q1 Results Exceeding Expectations
- Flat Sales Performance: In Q1 2026, Avantor reported net sales of $1.5814 billion, unchanged from Q1 2025, with a positive foreign currency impact of 4.1%, yet organic sales declined by 4.1%, indicating increased competitive pressure in the market.
- Net Income Decline: The company's net income fell from $64.5 million in Q1 2025 to $43.3 million, with a net income margin of 2.7%; adjusted net income was $114 million, reflecting a 26.6% year-over-year decrease, highlighting challenges in cost control and market conditions.
- Adjusted EBITDA Performance: Adjusted EBITDA stood at $219.4 million, with an EBITDA margin of 13.9%, down from 17.0% in the previous year, yet still demonstrating the company's ongoing efforts to enhance operational efficiency.
- 2026 Guidance Reaffirmed: Avantor reaffirmed its fiscal 2026 financial guidance, indicating management's confidence in future performance despite current challenges, and a commitment to improving execution and market share.
See More
Avantor Inc Stock Surpasses Analyst Target Price
- Stock Performance: Avantor Inc's shares recently traded at $9.69, surpassing the average analyst 12-month target price of $9.67, indicating increased market confidence that may attract more investor interest.
- Analyst Reaction: When a stock reaches its target price, analysts typically either downgrade their valuation or raise their target price; the current market response to Avantor may prompt analysts to reassess their targets to reflect improvements in the company's fundamentals.
- Target Price Distribution: Among the 15 analysts covered by Zacks, target prices range from $7.00 to $19.00, with a standard deviation of $3.154, highlighting varying market perspectives on Avantor's future performance, necessitating cautious evaluation by investors.
- Investor Decision-Making: As the stock price exceeds the target price, investors face a choice: to hold on for potentially higher targets or consider taking profits to avoid risks of overvaluation, which will influence future market dynamics.
See More
Avantor Appoints New Executive VP of Quality and Regulatory
- Executive Appointment: Avantor announced the appointment of Gerard Porreca as Executive Vice President of Quality and Regulatory, responsible for global quality assurance, quality systems, and regulatory affairs, aimed at enhancing the company's competitiveness in life sciences and advanced technology sectors.
- Extensive Experience: Porreca brings deep quality and regulatory experience from the life sciences, medical technology, and healthcare industries, having led global product approvals and complex regulatory engagements at Getinge, ensuring compliance in international markets.
- Strategic Importance: Avantor's CEO Emmanuel Ligner emphasized that Porreca's expertise will be crucial for enhancing operational capabilities and delivering mission-critical solutions, further solidifying Avantor's position as a trusted partner in the scientific journey.
- Customer Value Proposition: Porreca stated that quality and regulatory excellence are not just requirements but key value propositions for customers, and he aims to strengthen quality systems through data-driven insights to help clients accelerate the delivery of life-changing breakthroughs.
See More
Avantor Appoints New Executive VP of Quality and Regulatory
- Executive Appointment: Avantor has announced the appointment of Gerard Porreca as Executive Vice President of Quality and Regulatory, responsible for global quality assurance, quality systems, and regulatory affairs, aiming to enhance operational efficiency in the life sciences and advanced technology sectors.
- Extensive Experience: Porreca brings deep expertise in quality and compliance from his previous role at Getinge, where he led global product approvals and complex regulatory engagements, ensuring the company's compliance and competitiveness in international markets.
- Strategic Importance: CEO Emmanuel Ligner emphasized that Porreca's expertise will be vital for enhancing quality systems and delivering mission-critical solutions globally, thereby increasing customer trust and market position.
- Customer Value Proposition: Porreca stated that excellence in quality and regulatory affairs is not just a requirement but a key value proposition for customers, and he aims to leverage data-driven insights to strengthen quality systems and accelerate the delivery of life-changing breakthroughs.
See More
Avantor Q1 2026 Earnings Call Insights
- Financial Performance Exceeds Expectations: Avantor reported $1.581 billion in revenue for Q1 2026, down 4% year-over-year, yet improved execution in Bioscience and Medtech segments led to results surpassing expectations, with management reaffirming full-year guidance, indicating confidence in future growth.
- VWR Business Challenges: VWR Distribution and Services generated $1.15 billion in revenue for Q1, a 5% decline from the previous year; despite improvements in e-commerce traffic and conversion rates, the segment faces market pressures, with gradual growth expected in the second half of 2026.
- BMP Segment Performance: BMP revenue reached $431 million in Q1, down 2% year-over-year, but a book-to-bill ratio exceeding 1.1 indicates future growth potential; management anticipates Q2 will mark the low point for BMP growth amid increased competitive pressures.
- Leadership Changes and Strategic Adjustments: The company is refreshing its leadership team, with approximately 25% of management updated, the CFO set to depart next month, and the addition of a new Chief Digital Officer and Chief Transformation Officer aimed at accelerating the revival plan and enhancing operational efficiency.
See More
AVANTOR STOCK RISES 3.7% FOLLOWING STRONG Q1 EARNINGS REPORT
- Stock Performance: Avantor's shares increased by 3.7% following the announcement of their Q1 earnings report.
- Earnings Report: The rise in stock price was attributed to the company beating earnings expectations for the first quarter.
See More
Avantor Reports Strong Q1 Results Exceeding Expectations
- Flat Sales Performance: In Q1 2026, Avantor reported net sales of $1.5814 billion, unchanged from Q1 2025, with a positive foreign currency impact of 4.1%, yet organic sales declined by 4.1%, indicating increased competitive pressure in the market.
- Net Income Decline: The company's net income fell from $64.5 million in Q1 2025 to $43.3 million, with a net income margin of 2.7%; adjusted net income was $114 million, reflecting a 26.6% year-over-year decrease, highlighting challenges in cost control and market conditions.
- Adjusted EBITDA Performance: Adjusted EBITDA stood at $219.4 million, with an EBITDA margin of 13.9%, down from 17.0% in the previous year, yet still demonstrating the company's ongoing efforts to enhance operational efficiency.
- 2026 Guidance Reaffirmed: Avantor reaffirmed its fiscal 2026 financial guidance, indicating management's confidence in future performance despite current challenges, and a commitment to improving execution and market share.
See More
